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Background: X-linked agammaglobulinemia (XLA) is a primary immune deficiency characterized by recurrent
bacterial infections and profoundly depressed serum immunoglobulin levels and circulating mature B cells. It is
caused by mutations of the Bruton tyrosine kinase (BTK) gene and is the most common form of inherited antibody
deficiency. To our knowledge, this is the first report of XLA from Vietnam.
Methods: We investigated the BTK gene mutations and clinical features of four unrelated Vietnamese children.
Results: The mean ages at onset and at diagnosis were 2.5 and 8 years, respectively. All patients had a medical
history of otitis media, pneumonia, and septicemia at the time of diagnosis. Other infections reported included
sinusitis, bronchiectasis, arthritis, skin infections, meningitis, and recurrent diarrhea. We identified one previously
reported mutation (c.441G >A) and three novel mutations: two frameshifts (c.1770delG and c.1742 delG), and one
nonsense (c.1249A >T).
Conclusions: The delayed diagnosis may be attributable to insufficient awareness of this rare disease on the
background of frequent infections even in the immunocompetent pediatric population in Vietnam. Our results
further support the importance of molecular genetic testing in diagnosis of XLA.
Keywords: X-linked agammaglobulinemia, XLA, Bruton tyrosine kinase (BTK), Hypogammaglobulinemia, Mutation
analysis, Bruton diseaseBackground
X-linked agammaglobulinemia (XLA, OMIM 300300), first
described by Bruton in 1952, is a fully penetrant X-linked
recessive disorder characterized by recurrent bacterial
infections, profound hypogammaglobulinemia and marked
decrease in the number of B cells in the presence or ab-
sence of positive family history. It occurs in approximately
one in 200 000 individuals [1-5]. The gene responsible for
XLA is the Bruton Tyrosine Kinase (BTK) gene mapped to
the long arm of chromosome X in the region of Xq
21.3- q 22 [2,4,6-8]. The BTK gene is expressed in B cells
and moncytes throughout their differentiation but not in T
cells [9]. The gene contains 19 exons and encodes a protein
with five functional domains: plekstrin homology (PH) do-
main, Tec homology (TH) domain, Src homology 3 (SH3)* Correspondence: vvquang@hpmu.edu.vn
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domain [3-5]. According to the BTK database (http://rapid.
rcai.riken.jp/RAPID/mutation?pid_id=AGID_8), at present
592 unique BTK mutations have been found in XLA
patients. These mutations are found in both exons and
introns throughout the gene and may result in complete
absence of protein, or non functional proteins [4].
There have been very few reports of XLA from develop-
ing countries [10,11]. In Vietnam, after many years in war
and in low socio-economic conditions, we usually make a
diagnosis of XLA based on clinical manifestations, family
history, hypogammaglobulinemia, and low numbers of
circulating B cells, but not genetic analysis. In this study,
we report for the first time 4 Vietnamese boys with XLA,
confirmed by mutation analysis of the BTK gene in an
attempt to improve the diagnosis and management of XLA
in Vietnam.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Patients
Patient 1 presented with sepsis and erysipelas at age of
6 years. Several episodes per year of sinusitis, which were
treated by antibiotics for at least 2 months, were noted
between the age of 7 and 9 years. Patient 1 was diagnosed
as XLA at the age of 10 years. There was no lymphadenop-
athy and his tonsils were absent. Patient 1 had an elder
male sibling who died at 6 years old due to recurrent pneu-
monia and purulent meningitis. Chest X-ray showed lobar
pneumonia in the left lung. No organism could be isolated.
Patient 2 was well for the first 8 months of life. He then
had frequent pneumonia and sore throats. From 1 to
5 years of age, he had 3–4 episodes of otitis media, 4–5
episodes of pneumonia, and 1–2 episodes of erysipelas
every year, which were treated by antibiotics for at least
10 days. At the age of 6 years, patient 2 was referred to
the National Hospital of Pediatrics because of sepsis,
gastrointestinal hemorrhage, otitis media, and pneumonia.
His tonsils were hypoplastic. He had an elder male sibling
who was died at 9 years of age due to recurrent infections,
including pneumonia, otitis media, and dermatomyositis.
Patient 2 had an elder sister who was well.
From 9 months of age, patient 3 had recurrent otitis
media and mastoiditis that were operated on three
times (4, 7, and 9 years of age) at the National Hospital of
Pediatrics. However, he did not fully recover after the
operations. At 11 years old, patient 3 was referred to the
National Hospital of Pediatrics again due to septicemia
and purulent meningitis. His tonsils were absent. He had
no male sibling in the family and his female sibling was
normal.
Patient 4 was noted to have persistent diarrhea and
skin infections when he was 18 months old. From 2 to
4 years of age, he had 5–6 episodes of otitis media per
year. At 5 years of age, he was admitted to the National
Hospital of Pediatrics because of septicemia, persistent
coughing and otitis media and left knee arthritis. His
tonsils could not be visualized. His mother had a history
of lupus and two female siblings were normal.
Written informed consent for publication of these case
reports and accompanying images were obtained from
the patients’ parents. Copies of the signed informed con-
sent forms are available for review by the Editor of BMC
Pediatrics. Approval for the study was obtained from
Medical Ethics Council of Haiphong University of Medicine
and Pharmacy, and informed consent was obtained accord-
ing to the Declaration of Helsinki.
BTK mutation detection
We applied DNA sequencing protocols of the BTK gene
standardized at the Department of Human Genome
Research, Kazusa DNA Research Institute (http://rapid.
rcai.riken.jp/RAPID). In brief, genomic DNA was isolatedfrom whole blood by spin column purification (QIAGEN,
Valencia, CA, USA). All 19 exons of the BTK gene and the
exon-intron boundaries were amplified in individually or
in group yielding amplicons. Primer sequences are
available online (http://rapid.rcai.riken.jp/RAPID/dnaseq?
pid_id=AGID_8).
Polymerase chain reactions (PCR) were carried out in
10 μl containing 0.5 μl of genomic DNA, 5 pmol of each
primer, 5 μl of Multiplex PCR mix 2, 0.05 μl of Multiplex
PCR Mix 1 (TaKaRa Multiplex PCR assay Kit™; Takara,
Shiga, Japan). Cycling profiles used for all reactions
consisted of one hold at 94°C for 30 seconds followed by
30 cycles at 94°C for 30 seconds, 55°C for 10 seconds, 72°C
for 60 seconds, with a 5 minutes final extension at 72°C.
PCR products were purified by the ExoSAP-IT (USB,
Cleveland, OH, USA) according to the manufacturer’s
protocol. Sequencing was performed using the BigDye
deoxyterminator v3.1 cycle sequencing kit (Applied
Biosystems, Foster City, CA, USA) with an automated
ABI 3130 DNA sequencer. Detected mutations were
confirmed by sequencing in the opposite direction.
Numbering of nucleotide and amino acid position refers
to cDNA sequence (GenBank accession number NM_
000061.1), where the A of ATG translation initiation start
site represents nucleotide +1. Intron sequence information
was obtained from reference GenBank sequence (NG_
009616.1) [2-4].Results
Delayed diagnosis and severe recurrent bacterial infections
The clinical data collected prior to diagnosis are shown in
Table 1. The mean age at onset and at diagnosis was 2.5
and 8 years, respectively. All patients showed recurrent
infections; otitis media, pneumonia, and septicemia were
universally observed, followed by sinusitis (2/4), bronchi-
ectasis (2/4), arthritis (2/4), skin infection (2/4), meningitis
(2/4), and recurrent diarrhea (1/4). Tonsils were absent or
hypoplastic in all patients. Patients 1 and 2 had a positive
family history. Their brothers died of recurrent infections
at age of 6 and 9 years, respectively. No patients with a
positive family history were screened for XLA before onset
of infection.Low levels of circulating B cells and immunoglobulins
As shown in Table 2, all patients exhibited very low serum
immunoglobulin levels at diagnosis. No patients received
intravenous immunoglobulin (IVIG) substitution therapy
before diagnosis. The percentage of circulating B cells was
0–1.9%. Based on these clinical and laboratory findings,
our patients were clinically diagnosed with XLA. Neutro-
penia was observed in patient 4. The ratio of CD4+ to
CD8+ T cells was markedly inverted in patients 1 and 4.
Table 1 Clinical pictures of 4 XLA patients
Patient 1 2 3 4
Age at onset (y) 6 1 0.8 2
Age at diagnosis* (y) 10 6 11 5
Present age (y) 13 8 15 Died at 8 Y
Family history + + - -






Otitis media + + + +
Sinusitis + - + -
Pneumonia + + + +
Bronchiectasis + - + -
Arthritis + - - +
Skin infection + + - -
Septicemia + + + +
Meningitis/
encephalitis
+ - + -
Recurrent diarrhea - - - +
Tonsils Absent Hypoplastic Absent Hypoplastic
Duration of IVIG
treatment (m)
25 17 33 12
y, years; m, months; IVIG, intravenous immune globulin; +, yes; −, no.
*Age of confirmed agammaglobulinemia.
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To confirm the diagnosis, mutation analysis of the BTK
gene was performed (Table 3). Patients 1 and 3 were
found to carry novel frameshift mutations, c.1770delG
and c.1742delG, respectively. They were located in the
SH1 domain. Patient 2 had a novel nonsense mutation
(c.1249A > T), which was located in the SH2 domain. The
prevalent silent polymorphism affecting (c.1899 C > T)
was also observed in patient 2. Patient 4 carried a reported
mutation (c.441G > A) in the TH domain.Table 2 Immunological features of 4 XLA patients
Patient 1 2
WBC (×109/L) 15.1 9.4
Neutrophils (×109/L) 11.2 5.1
Lymphocytes (×109/L) 3.7 4,2
Ig (g/l)
IgG 0.06 2.18
IgA < 0.01 0.03
IgM < 0.01 0.21
CD19+ (%) (/μL) < 0.1 < 0.1
CD3+ (%) (/μL) 95 (3535) 93 (3564)
CD4+ (%) (/μL) 29 (1078) 45 (1707)
CD8+ (%) (/μL) 59 (2209) 37 (1404)
CD4+/CD8+ 0.49 1.22
WBC, white blood cells; Ig, immunoglobulin.Discussion
XLA is caused by a B-cell developmental defect. Being an
arrest of differentiation of pre-B cells to mature B cells,
pre-B cells are found in normal amounts while mature B
cells are nearly undetectable, that result in a pronounced
reduction of serum Ig of all classes. Therefore, affected
boys suffer from recurrent bacterial and enteroviral infec-
tions after six months of life after maternal antibodies are
no longer present in the infant’s circulation. Mutations in
all five domains of the BTK gene have been found to cause
XLA [6,12-16]. In the present study, we report four
Vietnamese boys with XLA and investigated the mutation
characteristics of their BTK gene.
The clinical manifestations of our XLA patients were
typical and similar to previous reports [5,8,10,11], with se-
vere recurrent infections (Table 1), low levels of mature B
cells and serum immunoglobulin (Ig) (Table 2). Pneumo-
nia, septicemia, otitis media were observed in all our pa-
tients. Bronchiectasis was present in patients 1 and 2,
possibly reflecting the delay of diagnosis with a complica-
tion of acute pneumonia in their histories. Patients 1 and
4 presented with arthritis, which was treated as juvenile
idiopathic arthritis before diagnosis of XLA; both patients
had markedly inverted CD4+/CD8+ ratio (Table 1). How-
ever, a relationship between inverted CD4+/CD8+ ratio
and arthritis is presently unclear. Similar to previous
reports [8,10,11], all our patients were diagnosed with
XLA late. The age of onset of infection was between
8 months and 6 years (mean 2.5 years). Nonetheless, the
age of diagnosis of XLA ranged from 5 to 11 years old
(mean 8 years), possibly reflecting the poor knowledge of
health workers about XLA and insufficient equipment for
diagnosis of XLA in Vietnam, such as flow cytometer.
Moreover, the delayed diagnosis may be because the dis-
ease is rare and infections (such as pneumonia, sinusitis,







< 0.1 1.9 (58) 6-25
89 (3982) 95 (2335) 55-84
36 (1616) 15 (367) 31-60
47 (2102) 73 (1792) 13-41
0.77 0.2 0.9-3.1
Table 3 BTK mutation analysis in 4 XLA patients
Patient Exon/Intron Mutation Protein domain Protein alteration Mother status
1 Exon 18 c.1770delG SH1 p.Gly594fsX54 N.D.
2 Exon 14 c.1249A > T* SH2 p.Lys417X N.D.
Exon 18 c.1899C > T** SH1
3 Exon 17 c.1742delG* SH1 p.Ala582LeufsX4 Carrier
4 Exon 6 c.441G > A TH p.Trp147X N.D.
*Novel mutation; **silent polymorphism; N.D., not done; SH1, catalytic kinase domains; SH2, Src homology 2 domain; TH, Tec homology domain.
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suggested that many XLA cases in Vietnam may be un-
diagnosed. Because early initiation of immunoglobulin
replacement therapy could prevent sequelae associated
with infections, early diagnosis is of great importance.
National networks and diagnostic guidelines for XLA may
be helpful for us to improve these issues.
Our XLA patients began to be treated with prophylactic
IVIG and appropriate antibiotics for acute and chronic in-
fections. Patients 1 and 2 were free from serious infections
with 400 and 300 mg/kg of IVIG replacement therapy
every 4 weeks, respectively. Patient 3 developed serious in-
fections frequently while he was receiving 300 mg/kg of
IVIG every month but was well after the dose had been
increased to 450 mg/kg. Patient 4 was well after 5 months
on 400 mg/kg of IVIG therapy every month; however, his
family decided to use traditional medicines instead of
IVIG at age of six. Patient 4 was hospitalized again with
multiple complications of serious infections; he died after
7 months despite reintroduction of treatment with IVIG
and antibiotics. Our results suggest that IVIG replacement
represents an important role to improve the prognosis of
XLA [10,11,17].
Our patients were examined for the presence of BTK
gene mutations. Their mutations were distributed in both
coding and non-coding (data not shown) regions of the
BTK gene, which were compatible with the range of muta-
tion as previously described [3-5,18,19]. Three out of 5
BTK mutations (60%) were located on SH1 domain
(Table 3). In accordance with previous reports [4,5,8,20],
their BTK mutations affected mainly SH1 domain; this
may be explained by the length of SH1 domain. There was
no correlation between clinical phenotype and the muta-
tion’s site, suggesting that other factors are contributing to
the phenotype and affecting the severity of disease, such
as other components of the BTK mediated signaling path-
way (μ heavy chain, λ5) and variants in proteins that func-
tion as part of the innate immune system [1,2,21].
Environmental and potentially epigenetic factors may also
contribute to the phenotype. We have analyzed the XLA
carrier status in mother of patient 3 and found the same
mutation. Because of the variability in clinical phenotype,
the diagnosis of XLA may be difficult in some cases with
atypical phenotype or without family history of disease. Insuch cases, molecular genetic testing provides an import-
ant tool for XLA confirmation and may allow accurate
carrier detection [2,5,8].
One out of 4 patients (25%) developed neutropenia dur-
ing the course of the disease. Several previous studies have
reported that about 10-27% of XLA patients might be
associated with neutropenia including mild, moderate and
severe neutropenia [22-25]. Patient 4 had two episodes of
moderate neutropenia before and at the time of diagnosis
of XLA (Table 2). The neutropenia durations of patient 4
were less than one week and resolved completely after
two weeks of treatment with antibiotic and IVIG therapy
suggesting the role of infections inducing neutropenia
[22,26]. This phenomenon can most probably be ex-
plained by reactive oxygen species- mediated apotosis of
neutrophils triggered by the engagement of innate recep-
tors and not by abnormal myeloid differentiation [27].
Conclusions
We describe four Vietnamese boys with typical phenotype
of XLA but delayed diagnosis. Our patients were defini-
tively diagnosed by genetic analysis. Their mutations are
three novel and one recurrent BTK mutations. This is the
first Vietnamese study describing clinical features and BTK
mutations in patients with XLA. The delayed diagnosis
may be attributable to insufficient awareness of this rare
disease on the background of frequent infections even in
the immunocompetent pediatric population in Vietnam.
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